Laserfiche WebLink
25 <br />the scientifically insufficient test specimen negative, the MRO must consider the <br />following: <br />1 A re-analysis of the original sample performed by the same laboratory; or <br />2 A re-analysis of the original sample to an alternate laboratory which is <br />certified in accordance with DHHS Guidelines; or <br />3 Consultation with the drug testing laboratory concerning the drug test <br />results. <br /> Under these circumstances, the MRO should conclude that the test is negative for the <br /> presence of a prohibited drug or drug metabolite in an individual’s system. <br /> <br />Retention of Samples and Retesting <br /> <br />Samples that yield positive results on confirmation must be retained by the laboratory in properly <br />secured, long term, frozen storage for at least 365 days as required by DOT procedures. Within <br />this 365 day period, the employee (or their representative) or the Company may request that the <br />laboratory retain the sample for an additional period. If, within the 365 day period, the <br />laboratory has not received a proper written request to retain the sample for a further reasonable <br />period specified in the request, the sample may be discarded following the end of the 365 day <br />period. <br /> <br />If the medical review officer (MRO) determines there is no legitimate medical explanation for a <br />confirmed positive test result other than the unauthorized use of a prohibited drug, the original <br />sample must be retested if the employee makes a written request for retesting within 60 days of <br />receipt of the final test result from the MRO. The employee may specify retesting by the original <br />laboratory or by a second laboratory that is certified by the Department of Heath and Human <br />Services. The Company may require the employee to pay in advance the cost of shipment (if <br />any) and reanalysis of the sample, but the employee must be reimbursed for such expense if the <br />retest is negative. <br /> <br />If the employee specifies retesting by a second laboratory, the second laboratory must be a <br />DHHS certified laboratory, and the original laboratory must follow approved NIDA chain of <br />custody procedures in transferring a portion of the sample. <br /> <br />Since some analytes may deteriorate during storage, detected levels of the drug below the <br />detection limits established in DOT procedures, but equal to or greater than the established <br />sensitivity of the assay, must, as technically appropriate, be reported and considered <br />corroborative of the original positive results. <br /> <br />Substance Abuse Professional <br /> <br />Trisco Systems, Inc. shall provide a Substance Abuse Professional for its employees and <br />supervisory personnel. <br /> <br />Employees who test positive on a drug test will be referred to Trisco Systems, Inc.’s Substance <br />Abuse Professional for assessment, referral and case monitoring and may be granted an unpaid <br />leave of absence to undertake rehabilitation treatment. An employee may use any accumulated